This correlates with the findings of Willes et al. who described that POLD3 downregulation is correlated with a poor cancer outcome [92] and those of Weberpals et al. who showed that POLD3 is overexpressed in patients with high-grade serous ovarian carcinoma and with good response to carboplatin/paclitaxel [93]. This evidence concerns the gene POLD3 and cancer.